Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for GeoVax Labs Inc. (GOVX : NSDQ)

• Company Description    GeoVax Labs Inc. is a clinical-stage biotechnology company. It engages in developing human vaccines against infectious diseases and cancer using a novel patented Modified Vaccinia Ankara-Virus Like Particle based vaccine platform. GeoVax Labs Inc. is based in ATLANTA, GA. Number of Employees: 17

• Price / Volume Information    Yesterday's Closing Price: $0.17 Daily Weekly Monthly 20 Day Moving Average: 3,732,439 shares Shares Outstanding: 30.06 (millions) Market Capitalization: $5.14 (millions) Beta: 3.67 52 Week High: $2.71 52 Week Low: $0.12 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -55.42% -55.35% 12 Week -71.50% -71.96% Year To Date 0.00% 0.00%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 1900 LAKE PARK DRIVE SUITE 380 - SMYRNA,GA 30080 USA ph: 678-384-7220 fax: 678-384-7281 investor@geovax.com http://www.geovax.com

• General Corporate Information    Officers David A. Dodd - Chief Executive Officer;President Mark W. Reynolds - Chief Financial Officer Randal D. Chase - Director Dean G. Kollintzas - Director Nicole Lemerond - Director Peer Information GeoVax Labs Inc. (CORR.) GeoVax Labs Inc. (RSPI) GeoVax Labs Inc. (CGXP) GeoVax Labs Inc. (BGEN) GeoVax Labs Inc. (GTBP) GeoVax Labs Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 373678606 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 09/01/25 Next Expected EPS Date: 03/26/26 Share - Related Items Shares Outstanding: 30.06 Most Recent Split Date: 1.00 (0.07:1) Beta: 3.67 Market Capitalization: $5.14 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.35 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-1.19 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 2.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 03/26/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 1.04 Price/Cash Flow: - Price / Sales: 0.84 EPS Growth vs. Year Ago Period: 65.93% vs. Previous Quarter: 11.43% Sales Growth vs. Year Ago Period: 183.06% vs. Previous Quarter: -47.95% ROE 12/31/25 - - 09/30/25 - -489.67 06/30/25 - -408.80 ROA 12/31/25 - - 09/30/25 - -325.85 06/30/25 - -279.89 Current Ratio 12/31/25 - - 09/30/25 - 3.57 06/30/25 - 2.03 Quick Ratio 12/31/25 - - 09/30/25 - 3.57 06/30/25 - 2.03 Operating Margin 12/31/25 - - 09/30/25 - - 06/30/25 - -403.88 Net Margin 12/31/25 - - 09/30/25 - - 06/30/25 - -403.88 Pre-Tax Margin 12/31/25 - - 09/30/25 - -755.26 06/30/25 - -403.88 Book Value 12/31/25 - - 09/30/25 - 0.17 06/30/25 - 0.18 Inventory Turnover 12/31/25 - - 09/30/25 - - 06/30/25 - - Debt-to-Equity 12/31/25 - - 09/30/25 - 0.00 06/30/25 - 0.00 Debt-to-Capital 12/31/25 - - 09/30/25 - 0.00 06/30/25 - 0.00

Powered by Zacks Investment Research ©